Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095574 | 1.00 | GSK3B (0.66) | GSK3B | |
| SCHEMBL3095652 | 1.00 | GSK3B (0.66) | GSK3B | |
| SCHEMBL1721205 | 1.00 | GSK3B (0.66) | GSK3B | |
| SCHEMBL3087713 | 1.00 | GSK3B (0.66) | GSK3B | |
| SCHEMBL1724888 | 0.86 | GSK3B (0.58) | GSK3B | |
| SCHEMBL13153667 | 0.86 | GSK3B (0.58) | GSK3B | |
| SCHEMBL3091328 | 0.84 | GSK3B (0.56) | GSK3B | |
| SCHEMBL1720880 | 0.84 | GSK3B (0.56) | GSK3B | |
| SCHEMBL1723979 | 0.84 | GSK3B (0.56) | GSK3B | |
| SCHEMBL3091339 | 0.84 | GSK3B (0.56) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071591-B2 | 7-cycloalkylaminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| US-8071591-B2 | 7-cycloalkylaminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| US-8071591-B2 | 7-cycloalkylaminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| WO-2010104205-A1 | 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234367-A1 | 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS | Kyorin Pharmaceuticals Co. Ltd | 2010-09-16 | — | — | US | disclosed |
| US-20100234367-A1 | 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS | Kyorin Pharmaceuticals Co. Ltd | 2010-09-16 | — | — | US | disclosed |
| US-20100234367-A1 | 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS | Kyorin Pharmaceuticals Co. Ltd | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234367-A1 | 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | GSK3B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.